Sentences with word «laherparepvec»

Efficacy and safety of talimogene laherparepvec neoadjuvant treatment plus surgery versus surgery alone for melanoma.

Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB - IV melanoma.

Our team was instrumental in the development of talimogene laherparepvec, the first in human oncolytic virus therapy for patients with melanoma.

Talimogene laherparepvec (T - VEC, trade name Imlygic) is a genetically engineered herpes simplex virus that preferentially targets cancer cells and then replicates within them while also causing the cells to produce the protein GM - CSF, which recruits immune cells and promotes their growth.

T - VEC, also called talimogene laherparepvec, is a human herpes simplex virus that is genetically engineered to bring T cells into a tumor and induce an antitumor response.

Our work was instrumental in several FDA approvals of breakthrough anti-cancer drugs (vemurafenib, dabrafenib + trametinib, vemurafenib + cobimetinib, pembrolizumab, talimogene laherparepvec) and resulted in almost 100 manuscripts, including New England Journal of Medicine, Lancet, Journal of Clinical Oncology, JAMA, Nature.

4.1 HSV - based Oncolytic Viruses 4.1.1 Imlygic; talimogene laherparepvec; T - Vec; OncoVEX (GM - CSF) 4.1.2 G47Δ 4.1.3 HF10; TB - 1401 4.1.4 HSV1716; seprehvir 4.1.5 HSV - Rb - p450 4.1.6 BV - 2711 4.1.7 ONCR - 001

The FDA has approved its first oncolytic virus therapy talimogene laherparepvec (Imlygic), a drug for the treatment of patients with melanoma lesions in the skin and lymph nodes.

The immunotherapy drugs are ipilimumab (Yervoy ®), pembrolizumab (Keytruda ®), nivolumab (Opdivo ®), and talimogene laherparepvec (T - VEC, Imlygic ™).

A multicenter, open - label trial of talimogene laherparepvec (T - VEC) plus pembrolizumab vs pembrolizumab monotherapy in previously untreated, unresected, stage IIIB - IV melanoma.

Responses of injected and uninjected lesions to intralesional talimogene laherparepvec (T - VEC) in the OPTiM study and the contribution of surgery to response.

The study consists of two phases and involves two promising immunotherapy drugs: pembrolizumab and talimogene laherparepvec (T - VEC).

Recently, it approved the first intralesional therapy, talimogene laherparepvec (T - VEC), for the treatment of metastatic melanoma lesions in the skin and lymph nodes.

To date, the only approved intralesional therapy for metastatic melanoma is talimogene laherparepvec (T - VEC), which has been shown to have a durable response not only in injected dermal, subcutaneous, and lymph node metastases, but also in noninjected regional metastases.

Primary overall survival from OPTiM, a randomized phase III trial of talimogene laherparepvec (T - VEC) versus subcutaneous granulocyte - macrophage colony - stimulating factor (GM - CSF) for the treatment of unresected stage IIIB / C and IV melanoma.

Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T - VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB - IV melanoma.

The combination of the attenuated oncolytic virus talimogene laherparepvec (T - VEC) and the immune checkpoint inhibitor pembrolizumab shows activity and is well tolerated by advanced melanoma patients, according to a new study presented at the Society for Melanoma Research 2015 International Congress, held November 18 — 21 in San Francisco.

In October 2015 — around the same time that the FDA was granting several approvals and indication extensions to checkpoint inhibitors — the agency approved the oncolytic virus (herpes simplex virus 1)-- derived therapy talimogene laherparepvec (T - VEC) for the treatment of melanoma lesions in the skin and lymph nodes.

Imlygic (talimogene laherparepvec), a first - of - its - kind therapy, showed promise against lesions in the skin and lymph nodes in an early trial, the FDA said Tuesday.